Brazil, Mexico Taking Divergent Paths On Regulatory Reform
Anvisa is in the process of trying to reduce some of its red tape, but the excessive bureaucracy at COFEPRIS is likely to remain in place for the foreseeable future.
You may also be interested in...
ANVISA's new resolution requires that companies importing finished drug products have their own quality control laboratory and warehouse.
Drug application backlog has been distraction for agency and prevents focus on other projects, says ANVISA General Manager of Drugs Raphael Sanches Pereira.
A recap of the latest Rx regulatory developments this summer (or winter) from Latin America regulators.